PATENT CLAIM ANALYSIS

Application Number: 15961408
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "419000"]

Abstract:
Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

Claim (Index 18):
The method of  claim 10 , wherein the \u03b17\u03b21 integrin modulatory agent is administered with an additional therapeutic agent.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 91.0
- Lexical Diversity: 2.23077
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15619256', '15382448', '14776898', '14426928', '13842781']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8565663634897063
- 35 USC 102 Novelty (BERT): 0.698546312010463
- Combined Prediction Score: 0.840764358341782
- Mean Citation Score: 709.7038959999999
- Max Citation Score: 771.6252
- Similarity Product: 698.7908267211914

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test